KAMES CAPITAL plc Reduces Position in Edwards Lifesciences (EW)

KAMES CAPITAL plc lessened its holdings in shares of Edwards Lifesciences (NYSE:EW) by 15.0% in the 1st quarter, HoldingsChannel reports. The fund owned 15,497 shares of the medical research company’s stock after selling 2,727 shares during the quarter. KAMES CAPITAL plc’s holdings in Edwards Lifesciences were worth $2,162,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Edwards Lifesciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 15,410,737 shares of the medical research company’s stock valued at $1,736,943,000 after purchasing an additional 331,896 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences by 45.7% in the 4th quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock valued at $854,444,000 after purchasing an additional 2,377,444 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in Edwards Lifesciences by 12.1% in the 4th quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock valued at $705,539,000 after purchasing an additional 675,216 shares during the last quarter. American Century Companies Inc. boosted its holdings in Edwards Lifesciences by 35.9% in the 1st quarter. American Century Companies Inc. now owns 2,789,721 shares of the medical research company’s stock valued at $389,222,000 after purchasing an additional 736,465 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Edwards Lifesciences by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 2,402,209 shares of the medical research company’s stock valued at $270,220,000 after purchasing an additional 93,049 shares during the last quarter. 81.03% of the stock is owned by institutional investors.

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 5,634 shares of the stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $134.91, for a total value of $760,082.94. Following the sale, the vice president now directly owns 38,784 shares of the company’s stock, valued at approximately $5,232,349.44. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Larry L. Wood sold 6,300 shares of the stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $137.26, for a total transaction of $864,738.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 231,400 shares of company stock worth $31,473,269. 1.84% of the stock is owned by company insiders.

Edwards Lifesciences opened at $135.95 on Monday, Marketbeat Ratings reports. The company has a market cap of $28.66 billion, a price-to-earnings ratio of 33.32, a price-to-earnings-growth ratio of 2.00 and a beta of 0.64. Edwards Lifesciences has a 52-week low of $100.20 and a 52-week high of $143.22. The company has a current ratio of 2.07, a quick ratio of 1.63 and a debt-to-equity ratio of 0.14.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. The company had revenue of $938.00 million for the quarter, compared to analyst estimates of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.94 EPS. equities analysts expect that Edwards Lifesciences will post 4.61 earnings per share for the current fiscal year.

Several brokerages have recently commented on EW. Zacks Investment Research lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, April 4th. SunTrust Banks restated a “buy” rating and issued a $180.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, April 10th. Canaccord Genuity restated a “buy” rating and issued a $174.00 price objective (up from $140.00) on shares of Edwards Lifesciences in a report on Friday, February 2nd. Cowen restated a “buy” rating and issued a $165.00 price objective on shares of Edwards Lifesciences in a report on Tuesday, March 20th. Finally, Barclays upped their price objective on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $148.53.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply